Impact of diagnostic hysteroscopy on peritoneal washing status and survival rate of patients with endometrial cancer

The diagnostic technique of hysteroscopy can spread the malignant cells from the uterus into the abdominal cavity in endometrial cancer patients. The study was designed to evaluate the impact of diagnostic hysteroscopy on the status of peritoneal cytology and prognosis of endometrial cancer patients. Pathologically confirmed endometrial cancer patients participated in this study. A matched 1:2 ratio control group was created with patients without hysteroscopy matched per cancer stage and histology grade. The presence of cancer cell in peritoneal fluid, the overall survival rate and disease-free survival rate between the two groups were compared. A total of 66 patients (23 cases and 43 controls) were included in the final analysis. Regarding the endometrial cancer type, 75.8% were endometroid, 9.1% papillary serous and 6.1% carcinosarcoma. Of these pateints 50%, 4.6%, 36.4% and 9.1% had stage I, II, III and IV cancer respectively. A total of 6 patients (9.1%) had peritoneal cytology with malignant cells, 3 (13%) were from the cases and 3 (7%) from the control group. The median follow-up period was 42.3 months. The 5-year overall survival rate for both groups was 79.8% with a similar 5-year survival rate of 83.2%. Gea Gzz General Hospital. Diagnostic hysteroscopy does not increase the risk of positive peritoneal cytology or worsen the prognosis of patients with endometrial cancer.

Endometrial cancer; Diagnostic hysteroscopy; Peritoneal cytology

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Nguyen PN, Nguyen VT. Evaluating clinical features in intracavitary uterine pathologies among Vietnamese women presenting with peri-and postmenopausal bleeding: a bicentric observational descriptive analysis. Journal of Mid-Life Health. 2022; 13: 225–232.

[3] Helou CM, Zhao Z, Ding T, Anderson TL, Harvey LFB. Should body mass index replace age to drive the decision for endometrial sampling in premenopausal women with abnormal uterine bleeding? Gynecological Endocrinology. 2022; 38: 432–437.

[4] Soucie JE, Chu PA, Ross S, Snodgrass T, Wood SL. The risk of diagnostic hysteroscopy in women with endometrial cancer. American Journal of Obstetrics and Gynecology. 2012; 207: 71.e1–71.e5.

[5] Al-Asadi FAHS, Jasim SK. Accuracy of office hysteroscopy in diagnosis of endometrial pathologies compared to ultrasound and histopathology in Baghdad Teaching Hospital. Journal of Population Therapeutics and Clinical Pharmacology. 2022; 29: e104–e108.

[6] Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA. 2002; 288: 1610–1621.

[7] Gkrozou F, Dimakopoulos G, Vrekoussis T, Lavasidis L, Koutlas A, Navrozoglou I, et al. Hysteroscopy in women with abnormal uterine bleeding: a meta-analysis on four major endometrial pathologies. Archives of Gynecology and Obstetrics. 2015; 291: 1347–1354.

[8] Chen J, Clark LH, Kong WM, Yan Z, Han C, Zhao H, et al. Does hysteroscopy worsen prognosis in women with type II endometrial carcinoma? PLOS ONE. 2017; 12: e0174226.

[9] Dovnik A, Crnobrnja B, Zegura B, Takac I, Pakiz M. Incidence of positive peritoneal cytology in patients with endometrial carcinoma after hysteroscopy vs. dilatation and curettage. Radiology and Oncology. 2016; 51: 88–93.

[10] Liu S, Zhen L, Zhang S, Cai Y, Lin Y, Chen F, et al. Comparison of prognosis of patients with endometrial cancer after hysteroscopy versus dilatation and curettage: a multicenter retrospective study. Frontiers in Medicine. 2023; 9: 1097133.

[11] Quintana-Bertó R, Padilla-Iserte P, Gil-Moreno A, Oliver-Pérez R, Coronado PJ, Martín-Salamanca MB, et al. Oncological safety of hysteroscopy in endometrial cancer. To be published in International Journal of Gynecologic Cancer. 2022. [Preprint].

[12] Behtash N, Sheikhhasani S, Nezamabadi V. Prognostic significance of positive peritoneal cytology in endometrial cancer patients. Journal of Obstetrics and Gynaecology. 2022; 42: 2336–2340.

[13] Sone K, Suzuki E, Taguchi A, Honjoh H, Nishijima A, Eguchi S, et al. Suspicious positive peritoneal cytology (class III) in endometrial cancer does not affect prognosis. Journal of Clinical Medicine. 2022; 11: 6527.

[14] Ueno Y, Toyoshima M, Shigemi D, Yumori A, Wakabayashi R, Kitagawa M, et al. Significance of positive peritoneal cytology for recurrence and survival in patients with endometrial cancer. The Journal of Obstetrics and Gynaecology Research. 2023; 49: 304–313.

[15] Liu YS, Wang HM, Gao Y. Controversy on positive peritoneal cytology of endometrial carcinoma. Computational and Mathematical Methods in Medicine. 2022; 2022: 1906769.

[16] Kanno M, Yunokawa M, Nakabayashi M, Omi M, Ikki A, Mizusaki M, et al. Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancer. Scientific Reports. 2022; 12: 166.

[17] Maricic S, Mandic A, Vasiljević T, Gutic B, Stevanovic N, Maksimovic T. Association of peritoneal cytology with other prognostic factors in endometrial cancer. Journal of Cytology. 2022; 39: 155–158.

[18] Nasioudis D, Ko EM, Cory L, Latif N. Impact of surgical approach on prevalence of positive peritoneal cytology and lymph-vascular invasion in patients with early-stage endometrial carcinoma: a National Cancer Database study. International Journal of Gynecological Cancer. 2021; 31: 1001–1006.

[19] Aumiphin J, Crochet P, Knight S, Carcopino X, Cravello L, Boubli L, et al. Outcome and follow-up of patients with endometrial carcinoma diagnosed on operative hysteroscopic resection specimens. Anticancer Research. 2016; 36: 4341–4345.

[20] Sáinz de la Cuesta R, Angel Espinosa JA, Crespo E, José Granizo JJ, Rivas F. Does fluid hysteroscopy increase the stage or worsen the prognosis in patients with endometrial cancer? A randomized controlled trial. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2004; 115: 211–215.

[21] Obermair A, Geramou M, Gücer F, Denison U, Graf AH, Kapshammer E, et al. Impact of hysteroscopy on disease-free survival in clinically stage I endometrial cancer patients. International Journal of Gynecological Cancer. 2000; 10: 275–279.

[22] Kudela M, Pilka R. Is there a real risk in patients with endometrial carcinoma undergoing diagnostic hysteroscopy (HSC)? European Journal of Gynaecological Oncology. 2001; 22, 342–344.

[23] Polyzos NP, Mauri D, Tsioras S, Messini CI, Valachis A, Messinis IE. Intraperitoneal dissemination of endometrial cancer cells after hysteroscopy: a systematic review and meta-analysis. International Journal of Gynecological Cancer. 2010; 20: 261–267.

[24] Lo KW, Cheung TH, Yim SF, Chung TK. Hysteroscopic dissemination of endometrial carcinoma using carbon dioxide and normal saline: a retrospective study. Gynecologic Oncology. 2002; 84: 394–398.

[25] Obermair A, Geramou M, Gucer F, Denison U, Graf AH, Kapshammer E, et al. Does hysteroscopy facilitate tumor cell dissemination? Cancer. 2000; 88: 139–143.

[26] Damião RDS, Lopes RGC, Santos ESD, Lippi UG, Fonseca EBD. Evaluation of the risk of spreading endometrial cell by hysteroscopy: a prospective longitudinal study. Obstetrics and Gynecology International. 2009; 2009: 397079.

[27] Solima E, Brusati V, Ditto A, Kusamura S, Martinelli F, Hanozet F, et al. Hysteroscopy in endometrial cancer: new methods to evaluate transtubal leakage of saline distension medium. American Journal of Obstetrics and Gynecology. 2008; 198: 214.e1–214.e4.

[28] Arikan G, Reich O, Weiss U, Hahn T, Reinisch S, Tamussino K, et al. Are endometrial carcinoma cells disseminated at hysteroscopy functionally viable? Gynecologic Oncology. 2001; 83: 221–226.

[29] Chang YN, Zhang Y, Wang YJ, Wang LP, Duan H. Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis. Fertility and Sterility. 2011; 96: 957–961.

[30] Zerbe MJ, Zhang J, Bristow RE, Grumbine FC, Abularach S, Montz FJ. Retrograde seeding of malignant cells during hysteroscopy in presumed early endometrial cancer. Gynecologic Oncology. 2000; 79: 55–58.

[31] Deluche E, Marti C, Jochum F, Bendifallah S, Azaïs H, Deidier J, et al. Application in France of the 2021 European recommendations on endometrial cancer. Bulletin of Cancer. 2023; 110: 55–68.

[32] Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2022; 33: 860–877.

[33] Wang PH, Yang ST, Liu CH, Chang WH, Lee FK, Lee WL. Endometrial cancer: part I. Basic concept. Taiwanese Journal of Obstetrics and Gynecology. 2022; 61: 951–959.

[34] Zammarrelli WA, Kim SH, Da Cruz Paula A, Rios-Doria EV, Ehmann S, Yeoshoua E, et al. Risk stratification of stage I grade 3 endometrioid endometrial carcinoma in the era of molecular classification. JCO Precision Oncology. 2022; 6: e2200194.

[35] Ebring C, Marlin R, Macni J, Vallard A, Bergerac S, Beaubrun-Renard M, et al. Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique. PLOS ONE. 2023; 18: e0278757.

[36] Tutkun Kilinc EC, Korkmaz V, Yalcin HR. Factor affecting lymph node metastasis in uterine papillary serous carcinomas: a retrospective analysis. Journal of Obstetrics and Gynaecology. 2022; 42: 3725–3730.